*The following content is generated by AI and is for reference only.
Alectinib, marketed under the brand name Alecensa, is a highly selective second-generation anaplastic lymphoma kinase (ALK) inhibitor developed for the treatment of ALK-positive non-small cell lung cancer (NSLK). Its chemical identity is defined by the molecular formula C27H30ClN5O2 and the CAS registry number 1186094-86-7. Structurally, it belongs to the class of pyrazolo[1,5-a]pyrimidine derivatives, engineered specifically to overcome resistance mechanisms associated with first-generation ALK inhibitors like crizotinib.
The primary clinical utility of Alectinib lies in its ability to inhibit the tyrosine kinase activity of ALK fusion proteins, which drive tumor growth in approximately 3-7% of NSCLC patients. By binding tightly to the ATP-binding pocket of the mutant ALK protein, it effectively blocks downstream signaling pathways responsible for cell proliferation and survival. A key advantage of this molecule is its superior blood-brain barrier penetration compared to earlier therapies. This property makes it particularly effective in managing and preventing central nervous system metastases, a common complication in advanced lung cancer where many drugs fail to achieve therapeutic concentrations.
Clinical trials have demonstrated that Alectinib significantly prolongs progression-free survival and overall survival in both treatment-naïve patients and those who have progressed on prior ALK inhibitors. It is approved globally as a first-line therapy for adult patients with locally advanced or metastatic ALK-positive NSCLC. Common side effects may include constipation, peripheral edema, fatigue, and elevated liver enzymes, though the drug generally exhibits a favorable safety profile relative to older generation agents. As research continues, Alectinib remains a cornerstone in precision oncology, exemplifying how targeted molecular therapies can dramatically improve outcomes for specific genetic subtypes of cancer. Ongoing studies are also exploring its potential in combination regimens and earlier disease stages to further optimize patient care.